Volume 31, Issue 3 (Avicenna Journal of Clinical Medicine-Autumn 2024)                   Avicenna J Clin Med 2024, 31(3): 153-160 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sharifi M, Ahmadi A, Manteghinejad A, Rezaeian Z. Incidence of Chemotherapy-Induced Fever and Neutropenia in Different Chemotherapy Regimens in Hospitalized Patients with Non-Metastatic Breast Cancer. Avicenna J Clin Med 2024; 31 (3) :153-160
URL: http://sjh.umsha.ac.ir/article-1-3081-en.html
Incidence of Chemotherapy-Induced Fever and Neutropenia in Different Chemotherapy Regimens in Hospitalized Patients with Non-Metastatic Breast Cancer
Mehran Sharifi1 , Arash Ahmadi2 , Amirreza Manteghinejad3 , Zahra Rezaeian3
1- Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2- Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran , ahmadi.arash1991@yahoo.com
3- Cancer Prevention Research Center, Deputy for Research & Technology, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract:   (1190 Views)
Background and Objective: Chemotherapy-induced fever and neutropenia are side effects of chemotherapy regimens that, in addition to disrupting the treatment process of patients, threaten their health as well. In this study, the prevalence of chemotherapy-induced fever and neutropenia in different chemotherapy regimens in hospitalized patients with non-metastatic breast cancer was investigated.
Materials and Methods: In this descriptive cross-sectional study, a total of 200 adult patients hospitalized at Seyed al-Shohada (Omid) Hospital in Isfahan, Iran, from 2016 to 2021 due to breast cancer were selected. These patients had received chemotherapy regimens including AC, AC-T, and TAXANE. The data were extracted from the breast cancer registry and the hospital's HIS systems and analyzed with the SPSS software at a 95% confidence level.
Results: The mean age of the patients was 46.90±11.28 years. The frequency of chemotherapy-induced neutropenia and fever was 15.5% and 9.5%, respectively. A significant relationship was observed between chemotherapy-induced fever and neutropenia with older age, higher cancer stage, and hypertension (P<0.05 for all). However, no significant relationship was found between the type of chemotherapy regimen and diabetes.
Conclusion: Chemotherapy-induced neutropenia and fever caused by neutropenia are relatively common side effects in breast cancer chemotherapy regimens. Older age, higher stage of cancer, and hypertension increased the prevalence of chemotherapy-induced neutropenia and neutropenia-induced fever.
 
Keywords: Breast Neoplasms, Drug Therapy, Fever, Neutropenia
Full-Text [PDF 1182 kb]   (422 Downloads)    
Type of Study: Original | Subject: Hematology & Oncology
Extended Abstract [HTM 23 KB]  (128 Download)
References
1. Jain V, Jain S, Mahajan S. Nanomedicines based drug delivery systems for anti-cancer targeting and treatment. Curr Drug Deliv. 2015;12(2):177-91. PMID: 25146439 DOI: 10.2174/1567201811666140822112516
2. Sancho-Garnier H, Colonna M. Breast cancer epidemiology. Presse Medicale (Paris, France. 1983.
3. Shamshirian A, Heydari K, Shams Z, Aref AR, Shamshirian D, Tamtaji OR, et al. Breast cancer risk factors in Iran: a systematic review & meta-analysis. Horm Mol Biol Clin Investig. 2020;41(4):20200021. PMID: 33079703 DOI: 10.1515/hmbci-2020-0021
4. Spei M-E, Samoli E, Bravi F, La Vecchia C, Bamia C, Benetou V. Physical activity in breast cancer survivors: a systematic review and meta-analysis on overall and breast cancer survival. Breast. 2019;44:144-52. PMID: 30780085 DOI: 10.1016/j.breast.2019.02.001
5. Liu Y-Q, Wang X-L, He D-H, Cheng Y-X. Protection against chemotherapy-and radiotherapy-induced side effects: A review based on the mechanisms and therapeutic opportunities of phytochemicals. Phytomedicine. 2021;80:153402. PMID: 33203590 DOI: 10.1016/j.phymed.2020.153402
6. Schirrmacher V. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment. Int J Oncol. 2019;54(2):407-19. PMID: 30570109 DOI: 10.3892/ijo.2018.4661
7. Sapkota B, Shrestha R, Chapagai S, Shakya DK, Bista P. Validation of risk of chemotherapy-induced neutropenia: experience from oncology hospital of Nepal. Cancer Manag Res. 2020:3751-8. DOI: 10.2147/CMAR.S243916#d1e181
8. Boccia R, Glaspy J, Crawford J, Aapro M. Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed? Oncologist. 2022;27(8):625-636. PMID: 35552754 DOI: 10.1093/oncolo/oyac074
9. Kasi PM, Grothey A. Chemotherapy-induced neutropenia as a prognostic and predictive marker of outcomes in solid-tumor patients. Drugs. 2018;78:737-45. DOI: 10.1007/s40265-018-0909-3
10. Pelzer F, Tröger W. Complementary treatment with mistletoe extracts during chemotherapy: safety, neutropenia, fever, and quality of life assessed in a randomized study. J Altern Complement Med. 2018;24(9-10):954-61. PMID: 30247950 DOI: 10.1089/acm.2018.0159
11. Van Dooijeweert C, van der Wall E, Baas I. Chemotherapy-induced febrile neutropenia: primary G-CSF prophylaxis indicated during docetaxel cycles. Neth J Med. 2019;77(77):7. Link
12. Theyab A, Algahtani M, Alsharif KF, Hawsawi YM, Alghamdi A, Alghamdi A, et al. New insight into the mechanism of granulocyte colony-stimulating factor (G-CSF) that induces the mobilization of neutrophils. Hematology. 2021;26(1):628-36. [DOI: 10.1080/16078454.2021.1965725]
13. Lyman G, Yau L, Nakov R, Krendyukov A. Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support. Ann Oncol. 2018;29(9):1903-10. PMID: 30099478 DOI: 10.1093/annonc/mdy311
14. Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33(28):3199-212. PMID: 26169616 DOI: 10.1200/JCO.2015.62.3488
15. Salako O, Okunade KS, Adeniji AA, Fagbenro GT, Afolaranmi OJ. Chemotherapy induced neutropenia and febrile neutropenia among breast cancer patients in a tertiary hospital in Nigeria. Ecancermedicalscience. 2021;15:1188. PMID: 33777181 DOI: 10.3332/ecancer.2021.1188
16. Bacrie J, Laurans M, Iorio P, Fourme E, Volters AB, Bozec L, et al. Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution. Support Care Cancer. 2018;26:4097-103. DOI: 10.1007/s00520-018-4280-4
17. Hutajulu SH, Oktariani S, Sunggoro AJ, Bintoro BS, Astari YK, Wiranata JA, et al. The occurrence and risk factors of chemotherapy-induced neutropenia in patients with breast cancer not receiving primary G-CSF prophylaxis. Ecancermedicalscience. 2023;17:1618. PMID: 38414951 DOI: 10.3332/ecancer.2023.1618
18. Savarese D. Common terminology criteria for adverse events. UpToDate Waltham, MA: UpToDate. 2013:1-9. Link
19. Joseph A, Joshua JM, Mathews SM. Chemotherapy-induced neutropenia among breast Cancer patients in a tertiary care hospital: Risk and consequences. J Oncol Pharm Pract. 2023;29(3):529-33. DOI: 10.1177/10781552221074004
20. Razzaghdoust A, Mofid B, Zangeneh M. Predicting chemotherapy-induced thrombocytopenia in cancer patients with solid tumors or lymphoma. J Oncol Pharm Pract. 2020;26(3):587-94. DOI: 10.1177/1078155219861423
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Avicenna Journal of Clinical Medicine

Designed & Developed by : Yektaweb